TENOSYNOVIAL GIANT CELL TUMOR
Clinical trials for TENOSYNOVIAL GIANT CELL TUMOR explained in plain language.
Never miss a new study
Get alerted when new TENOSYNOVIAL GIANT CELL TUMOR trials appear
Sign up with your email to follow new studies for TENOSYNOVIAL GIANT CELL TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill for tough tumors enters first human tests
Disease control Recruiting nowThis early-stage study tests an experimental pill called ABSK021 in people with advanced solid tumors (including a rare joint tumor called TGCT) who have run out of standard options. The main goal is to check safety and find the right dose, while also seeing if the drug can shrin…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE1 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for rare joint tumor: experimental drug targets stubborn growths
Disease control Recruiting nowThis study tests an experimental drug called pimicotinib in 20 Japanese adults with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous tumor that grows around joints and can cause pain and stiffness. The drug aims to shrink the tumor and improve symptoms. Participants mu…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE2 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
Glow-in-the-Dark dye could help surgeons spot hidden tumors
Diagnosis Recruiting nowThis study tests whether a green dye, injected before surgery, can make tenosynovial giant cell tumors glow under a special camera. Surgeons will use the glow to find and remove all tumor tissue during the operation. The goal is to see if this technique improves how completely tu…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE4 • Sponsor: Shanghai Jiao Tong University Affiliated Sixth People's Hospital • Aim: Diagnosis
Last updated May 15, 2026 11:53 UTC
-
New study digs deeper into TURALIO's liver risks for TGCT patients
Knowledge-focused Recruiting nowThis study looks at the long-term risk of severe liver damage in people with a type of tumor called TGCT who have taken the drug TURALIO (pexidartinib) and already had liver test problems. Researchers will track about 30 adults to see how often liver failure occurs after stopping…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Sponsor: Daiichi Sankyo • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC
-
New study tracks Real-Life use of TGCT drug vimseltinib
Knowledge-focused Recruiting nowThis study watches how people with tenosynovial giant cell tumor (TGCT) use vimseltinib in real-world settings. Researchers will track treatment patterns and quality of life without changing standard care. About 100 participants will join, and the study does not test new treatmen…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Knowledge-focused
Last updated May 11, 2026 20:48 UTC